key: cord-0710947-a83szurq
authors: Yadav, Pragya D; Kumar, Sanjay
title: Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy
date: 2021-11-23
journal: Lancet Infect Dis
DOI: 10.1016/s1473-3099(21)00687-3
sha: 6c7804a0764b16ae48d7d88557465b83453d8ad3
doc_id: 710947
cord_uid: a83szurq

nan

Apart from COVID-19-appropriate behaviour, effective vaccine coverage is the single most important intervention needed to control the ongoing SARS-CoV-2 pandemic. Although several vaccines are being used under emergency use authorisation, worldwide vaccination coverage will only be achieved when vaccine availability exceeds vaccine demand. Globally, several prominent institutions, universities, and leading pharmaceutical companies have successfully developed COVID-19 vaccine candidates that have progressed to clinical trials. In The Lancet Infectious Diseases, Peter G Kremsner and colleagues 1 report data on the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate from a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial in ten countries in Europe and Latin America (HERALD).

Between Dec 11, 2020, and April 12, 2021, 39 680 COVID-19-naive adults (aged ≥18 years) were randomly assigned to receive two doses of either CVnCoV or placebo on days 1 and 29, of whom 39 529 received at least one dose of CVnCoV (n=19 783) or placebo (n=19 746). The primary efficacy endpoint was the occurrence of virologically confirmed COVID-19 of any severity caused by any strain from 15 days after the second dose. Key secondary endpoints were the occurrence of virologically confirmed moderate-to-severe COVID-19 or severe COVID-19. Solicited local and systemic adverse events for 7 days after each dose and unsolicited adverse events for 28 days after each dose were monitored as primary safety outcomes.

A total of 228 participants developed COVID-19 of any severity over the course of follow-up, of whom 83 were in the CVnCoV group and 145 were in the placebo group. Vaccine efficacy against symptomatic disease of any severity was 48·2% (95·826% CI 31·0-61·4) and 70·7% (95% CI 42·5-86·1) against moderate-to-severe COVID-19. Sequencing data showed that about 97% of COVID-19 cases were caused by variants of concern (ie, alpha [B. The US Food and Drug Administration issued emergency use authorisation for two mRNA vaccinesnamely, BNT162b2 2 (Pfizer-BioNtech) and mRNA-1273 3 (Moderna)-for roll out in the USA in December, 2020. The efficacies of the BNT162b2 and mRNA-1273 vaccines, with doses administered 21-28 days apart, were 91·1% and 94·1%, respectively, against COVID-19. 2,3 Although these two vaccines showed high efficacy, the trials were done before the emergence of SARS-CoV-2 variants of concern. Variants of concern, especially delta and its derivatives, are the main reason for breakthrough infections globally. Studies have reported breakthrough infections with SARS-CoV-2 variants of concern among BNT162b2-vaccinated and mRNA-1273-vaccinated individuals. 4 Therefore, a potential reason for the lower efficacy of CVnCoV compared with BNT162b2 and mRNA-1273 is immune escape by SARS-CoV-2 variants. The available data on breakthrough cases of SARS-CoV-2 suggest the need for booster vaccinations to cope with a waning immune response and emerging SARS-CoV-2 variants.

Unlike conventional vaccines, mRNA vaccines are easy to administer, mimic natural infection, cannot become infectious, and are cost-effective to produce at a larger scale. However, higher doses of mRNA vaccines have been shown to increase the rate and severity of adverse events in animal studies. 5 Furthermore, data on the comparative safety of different mRNA vaccines are lacking. For lowincome countries, the logistics and expenses involved in storing and maintaining mRNA vaccines at low temperatures are challenging. Although mRNA vaccines have been shown to elicit efficacious immune responses in animal models against Zika, rabies, and influenza viruses, 6, 7 to date, only two mRNA-based vaccines have been approved for COVID-19. 2, 3 To meet the demand of a global population, sufficient doses will need to be produced within a short amount of time, which will only be feasible with collaboration between vaccine developers and multiple vaccine manufacturers across the globe.

Although the efficacy of CVnCoV against COVID-19 partly met the vaccine efficacy criteria of WHO, the time interval for follow-up of 15 days after receiving the second dose was very short. Whether the humoral immune response waned post-vaccination could not be evaluated within such a short period. In February, 2021, Noa and colleagues 8 reported a vaccine efficacy of 46% for BNT162b2 in Israel in a real-world scenario. This waning in vaccine efficacy after 6 months in a fully vaccinated population has been attributed to declining humoral immunity and immune escape due to the delta variant. CVnCoV has been withdrawn from regulatory review by its manufacturer and how it would have performed in the real world will now never be known.

Vaccine efficacy could be improved via a heterologous boost regimen using vaccines based on two different platforms; 9,10 Xinxue Liu and colleagues 10 showed that immunogenicity was higher for heterologous schedules of adenovirus vector-based and mRNA-based vaccines compared with homologous prime-boost schedules. Rather than waiting for higher efficacy vaccines or newer vaccines, existing vaccines could be used in combination with vector-based vaccines in a heterologous boost regimen or as a booster dose to enhance vaccine availability in low-income and middle-income countries to help to end the pandemic.

We declare no competing interests.

India (PDY); Department of Neurosurgery, Command Hospital (Southern Command), Armed Forces Medical College

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Hospitalisation among vaccine breakthrough COVID-19 infections

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

Modified mRNA vaccines protect against Zika virus infection

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting

Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial